Tuesday, April 30, 2013
Auxilium Pharmaceuticals Inc. of Chesterbrook, Pa., reported net revenues of $66.2 million for the first quarter ending March 31, compared to net revenues of $73.6 million in the first quarter of 2012. The decrease was attributed to a fall in U.S. sales of Xiaflex (collagenase clostridium histolyticum, or CCH) and Testim. On a U.S. GAAP basis, Auxilium reported net loss of $8.2 million, or 17 cents per share, compared to a net loss of $1.7 million, or 4 cents per share, in the same period a year earlier.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.